Group 1 - The company's stock (stock code: 002688) experienced an abnormal trading fluctuation, with a cumulative price increase of 26.48% over three consecutive trading days from April 1 to April 3, 2025 [2] - The company conducted a self-examination and confirmed that there were no corrections or supplements needed for previously disclosed information [3] - The company did not find any recent media reports that could have significantly impacted the stock price [4] Group 2 - The company's operational situation and external business environment have not undergone any significant changes recently [5] - The company and its major shareholders have not engaged in any undisclosed significant matters related to the company during the abnormal trading period [5] - The board confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange regulations [6] Group 3 - The company is in the process of preparing its 2024 annual report and 2025 Q1 report, which will be disclosed on April 26, 2025 [7] - The company has not provided any undisclosed performance information to third parties outside of its auditing firm [7] - The designated information disclosure media for the company includes several financial newspapers and websites [7]

证券代码：002688 证券简称：金河生物 公告编号：2025-012 金河生物科技股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 公司董事会确认，截至本公告披露日，公司目前没有任何根据《深圳证券交 易所股票上市规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹 划、商谈、意向、协议等；董事会也未获悉公司有根据《深圳证券交易所股票上 市规则》等有关规定应予以披露而未披露的、对公司股票及其衍生品种交易价格 一、股票交易异常波动的情况介绍 金河生物科技股份有限公司（以下简称"公司"）股票（股票简称：金河生 物，股票代码：002688）交易价格于2025年4月1日、4月2日、4月3日连续三个交 易日收盘价格涨幅偏离值累计26.48%，根据深圳证券交易所的相关规定，属于股 票交易的异常波动情形。 二、公司关注并核实的情况 针对公司股票交易异常波动的情况，公司董事会就相关事项进行了自查，并 向控股股东、实际控制人及其一致行动人进行了核实，现就有关情况说明如下： 1、公司前期所披露的信息，不存在需要更正、补充之 ...

Core Viewpoint - The company, Jinhe Biological, announced a price adjustment plan for its end products in response to the recent U.S. tariffs on certain raw pharmaceutical products from China, aiming to maintain product quality and service while maximizing profitability in the U.S. market [1][2] Group 1: Company Strategy - Jinhe Biological will conduct thorough market research to timely increase the end sales prices of its products in the U.S. to offset the cost impact from the tariff hikes [1] - The company emphasizes strict quality control in production to gain customer trust and expand market share, ultimately enhancing economic benefits [1][2] Group 2: Market Position and Products - As a leading supplier of chlortetracycline premix, Jinhe Biological's services cover three main areas: animal protection, environmental protection, and agricultural product processing [2] - The company offers over 90 products, including chlortetracycline series animal protection products, corn starch, and various vaccines, with an annual comprehensive production capacity of 60,000 tons for its "Muxing" brand chlortetracycline premix [2] Group 3: Market Impact - Following the announcement of the price adjustment plan, Jinhe Biological's stock price opened with a 10% increase, reaching 5.94 yuan per share, with a total market capitalization of 4.584 billion yuan [2]

证券代码：002688 证券简称：金河生物 公告编号：2025-011 金河生物科技股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于近日收到控股股东内蒙 古金河控股有限公司（以下简称"金河控股"）的通知，获悉金河控股所持有本 公司的部分股份解除质押。具体事项如下： 一、股东股份解除质押基本情况 | 股东名称 | 是否为控股股东 | 本次解除 | 占其所 | 占公司 | 质押开始 | 质押解除日 | | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 或第一大股东及 | 质押股份 | 持股份 | 总股本 | 日期 | 期 | | | | | 其一致行动人 | 数量 | 比例 | 比例 | | | | | | 金河控股 | 是 | 20,036,000 | 8.29% | 2.60% | 2022 年 07 | 2025 | 年 3 月 | 华西证券股 | | | | | | ...

Investment Rating - The report gives a "Buy" rating for the company, Jinhe Biological (stock code: 002688.SZ) [2][44]. Core Views - Jinhe Biological is a leading enterprise in the veterinary antibiotic sector, focusing on a dual-driven strategy of chemical drugs and vaccines. The company has expanded its business boundaries from veterinary raw materials to animal vaccines and environmental technology, forming a new business pattern with organic interaction among various segments [4][6][11]. - The company achieved revenue of 2.174 billion yuan in 2023, with a year-on-year growth of 2.42%, and 1.065 billion yuan in the first half of 2024, growing by 3.22% year-on-year [4][7]. - The veterinary chemical drug business remains the largest revenue contributor, while the vaccine business is expected to grow significantly as product penetration increases [44]. Summary by Sections Company Overview - Jinhe Biological was established in 1988 and has become a global leader in animal health. The company went public in 2012 and has since expanded into animal vaccines and environmental technology, creating a comprehensive animal health ecosystem [6][8]. Financial Performance - In 2023, the company reported a revenue of 2.174 billion yuan, with a projected revenue of 2.289 billion yuan in 2024, representing a growth rate of 5.30% [5][45]. - The net profit attributable to the parent company is expected to grow from 864.6 million yuan in 2023 to 1.8691 billion yuan in 2025, reflecting a growth rate of 45.47% [5][44]. Business Segments - The veterinary chemical drug segment generated 1.016 billion yuan in revenue in 2023, with a year-on-year increase of 3.27%, maintaining stable growth [11][24]. - The veterinary biological products segment achieved revenue of 335 million yuan in 2023, with a year-on-year growth of 1.48% [35]. Growth Drivers - The company is enhancing its production capacity, with a new project expected to add 60,000 tons of chemical drug capacity by October 2024, increasing total production capacity to 115,000 tons [24][29]. - Jinhe Biological is actively expanding its pet business, establishing a subsidiary in Shanghai in 2024, with several products already on the market and more in development [19][24]. Research and Development - The company has invested in R&D, with 74 million yuan spent in 2023, focusing on innovation and product quality improvement [19][24]. - Jinhe Biological has a rich pipeline of over 20 vaccine products in development, including vaccines for pigs and pets, which are expected to contribute to future revenue growth [40][42].

Group 1 - China Aluminum reported a net profit of 12.4 billion yuan for 2024, an increase of 85.38% year-on-year, with a proposed cash dividend of 0.135 yuan per share [1] - Lihua Technology's net profit for 2024 decreased by 25.41% to 245 million yuan, with a proposed cash dividend of 0.7 yuan per 10 shares [1][2] - Zhongjing Food achieved a net profit of 175 million yuan in 2024, up 1.81% year-on-year, proposing a cash dividend of 8 yuan per 10 shares [3][4] - Sanwei Chemical's net profit fell by 6.92% to 263 million yuan, with a proposed cash dividend of 3 yuan per 10 shares [5] - Meino Biological's project for corn protein processing has received construction approval, with an investment of approximately 391 million yuan [6][7] Group 2 - Guangdian Electric's net profit surged by 411.28% to 74.73 million yuan, proposing a cash dividend of 0.7 yuan per 10 shares [13][14] - Xin'ao Co. reported a net profit of 4.493 billion yuan for 2024, down 36.64%, with a proposed cash dividend of 10.3 yuan per 10 shares [15] - Huaren Pharmaceutical's subsidiary received approval for a raw material drug, enhancing its product line [16] - Huanxin Technology received a project confirmation from BAIC Group for two display screen products, expected to enter mass supply [17] - Haitong Development plans to purchase four bulk carriers for a total of 59.25 million USD to expand its fleet [18] Group 3 - Guochuang High-tech won a bid for an asphalt procurement project worth 128 million yuan [22][23] - Huayi Pharmaceutical's subsidiary received overseas marketing approvals for several products [24] - Haisco's innovative drug HSK41959 has received clinical trial approval [25] - Hetai Machinery's subsidiary obtained a patent for a dust-proof chain technology [28] - Le Xin Medical's fetal heart rate monitor registration renewal application has been accepted [29] Group 4 - Feilong Co. became a designated supplier for an international client's electronic oil pump project, with expected sales of approximately 160 million yuan [29] - Yunnan Copper reported a net profit of 1.265 billion yuan for 2024, down 19.9%, with a proposed cash dividend of 2.4 yuan per 10 shares [42] - China Merchants Bank's net profit increased by 1.22% to 148.39 billion yuan, proposing a cash dividend of 20 yuan per 10 shares [43] - Shuanghui Development's net profit decreased by 1.26% to 4.989 billion yuan, with a proposed cash dividend of 7.5 yuan per 10 shares [44]

证券代码：002688 证券简称：金河生物 公告编号：2025-009 一、股东股份质押的基本情况 二、股东股份累计质押的情况 截至公告披露日，控股股东金河控股及其一致行动人路牡丹、王志军、路漫 | 漫、王晓英所持质押股份情况如下： | | --- | 金河生物科技股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于近日收到控股股东内蒙 古金河控股有限公司（以下简称"金河控股"）的通知，获悉金河控股所持有本 公司的部分股份质押。具体事项如下： | 股东 | 是否为控股 股东或第一 | 本次质押数 | 占其所 持股份 | 占公司 总股本 | 是否 为限 | 是否为 补充质 | 质押开始 | 质押到期 | 质权人 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 大股东及其 | 量（股） | | | | | 日期 | 日 | | 用途 | | | 一致行 ...

金河生物科技股份有限公司（以下简称"公司"）子公司金河佑本生物制品 有限公司（以下简称"金河佑本"）于近日获得由国家知识产权局颁发的发明专 利证书，具体情况如下： 1、证书号：第 7754581 号 2、发明名称：一种犬瘟热病毒和犬细小病毒的二联亚单位疫苗及其制备方 法和应用 证券代码：002688 证券简称：金河生物 公告编号：2025-010 金河生物科技股份有限公司 关于子公司取得发明专利证书的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 特此公告。 金河生物科技股份有限公司 董 事 会 3、专利权人：金河佑本生物制品有限公司 4、地址：010000 内蒙古自治区呼和浩特市和林格尔县盛乐经济园区盛乐五 街北(北奇公司东) 5、发明人：李雪峰；康斌；郭海军；武玉梅；董鹏；张金龙；赵炳武；王 家福 6、专利号：ZL 2022 1 1403119.4 7、专利申请日：2022 年 11 月 10 日 8、授权公告号:CN 116059338 B 9、授权公告日：2025 年 02 月 25 日 本发明创新地实现了一次表达纯化过程即可同时生产 ...

2025年3月20日，公司已将用于暂时补充流动资金的闲置募集资金人民币 1,300万元提前归还至公司募集资金专用账户，此次归还的募集资金使用期限未超 过12个月，在使用期间对资金进行了合理的安排，资金运用情况良好。公司已将 上述募集资金的归还情况通知了保荐机构及保荐代表人。 截至本公告披露日，公司已累计归还暂时补充流动资金的闲置募集资金人民 币1,300万元，剩余暂时补充流动资金的8,700万元闲置募集资金将在规定期限内归 还，届时将履行相关信息披露义务。 证券代码：002688 证券简称：金河生物 公告编号：2025-008 金河生物科技股份有限公司 关于提前归还部分暂时补充流动资金的闲置募集资金的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于2024年9月23日召开第六 届董事会第十八次会议及第六届监事会第十五次会议，审议通过了《关于使用部 分闲置募集资金暂时补充流动资金的议案》，同意公司在保证不变相改变募集资 金用途且不影响募集资金投资项目正常进行前提下，使用不超过人民币10,000万 元 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-007 金河生物科技股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于近日获得由国家知识产 权局颁发的发明专利证书，具体情况如下： 1、证书号：第7806654号 2、发明名称：金色链霉菌发酵用酵母的发酵方法、发酵产物及其应用 3、专利权人：金河生物科技股份有限公司 4、地址：010200 内蒙古自治区呼和浩特市托克托县双河镇新坪路71号 5、发明人：谢昌贤；王鹏飞；张宝林；陈红梅；王春云；王楠；高俊霞 2025 年 3 月 18 日 1 6、专利号：ZL 2024 1 1657685.7 7、专利申请日：2024年11月20日 8、授权公告号:CN 119144470 B 9、授权公告日：2025年03月18日 本发明提供一种金色链霉菌发酵用酵母的发酵方法，通过该发酵方法有助于 提高酵母产量，降低金色链霉菌发酵成本。同时，本发明还提供了一种酵母发酵 产物的处理方法，解决了酵母发酵产物后处理步骤繁琐、 ...